Thieler Law Corp advises investors with losses exceeding $100,000 of the January 2, 2020 lead plaintiff deadline in a class action lawsuit filed against Abeona Therapeutics Inc (NASDAQ: ABEO) (“Abeona” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Abeona Therapeutics Inc securities between May 31, 2018 and September 23, 2019, have until January 2, 2020 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Abeona Therapeutics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Abeona’s Chemical, Manufacturing and Controls (“CMC”) and internal controls and procedures and/or compliance policies were inadequate; the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or such transport stability was insufficient; it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would reject approval for the start of the VITAL Study until such issues were addressed; and as a result, Abeona’s public statements were materially false and misleading at all relevant times.

On September 23, 2019, the Company announced receipt of a clinical hold letter from the U.S. Food and Drug Administration (“FDA”), “clarifying that the FDA will not provide approval for the Company to begin its planned Phase 3 clinical trial for EB-101 until it submits to the FDA additional data points on transport stability of EB-101 to clinical sites.”

Following this news, NASDAQ: ABEO fell $0.39 per share, or 11.96%, to close at $2.87 per share on September 23, 2019.

If you were negatively impacted by your investment in Abeona Therapeutics Inc securities between May 31, 2018 and September 23, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185